Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profile of ANB020 Administered to Adult Subjects With Moderate-to-Severe Atopic Dermatitis
Phase of Trial: Phase II
Latest Information Update: 21 Dec 2018
At a glance
- Drugs Etokimab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms ATLAS
- Sponsors AnaptysBio
- 07 Aug 2018 According to an AnaptysBio media release, data from this study is expected in second half of 2019.
- 08 May 2018 Status changed from planning to recruiting, as reported in an AnaptysBio media release.
- 11 Oct 2017 New trial record